Management of Fetal Cardiac Arrhythmia Diagnosed In Utero
Most fetal arrhythmias are benign and require only close surveillance, but sustained tachyarrhythmias with hydrops fetalis or heart failure require immediate transplacental antiarrhythmic therapy to prevent fetal demise.
Initial Assessment and Risk Stratification
When fetal arrhythmia is detected, immediately perform detailed fetal echocardiography using M-mode and Doppler to:
- Determine the specific arrhythmia type (premature contractions, tachyarrhythmia, or bradyarrhythmia)
- Assess for structural heart disease
- Evaluate for hydrops fetalis (ascites, pleural/pericardial effusion, skin edema)
- Measure ventricular function and cardiac output 1, 2
The simultaneous Doppler recording of superior vena cava and ascending aorta is particularly useful for assessing atrioventricular intervals 3.
Management by Arrhythmia Type
Premature Atrial Contractions (PACs)
Low-risk isolated PACs (90% of fetal arrhythmias) require only weekly heart rate monitoring with routine obstetric care 4.
High-risk features requiring enhanced surveillance include:
- Blocked PACs
- Bigeminy or trigeminy patterns
- Frequent PACs or bursts of tachycardia
- Atrial septal aneurysm
- Heart failure or structural heart disease 4
Supraventricular Tachycardia (SVT) and Atrial Flutter
For sustained fetal tachycardia (>180 bpm), initiate transplacental digoxin as first-line therapy 5, 1, 3.
Treatment Algorithm:
Without hydrops fetalis:
- Start with digoxin (first-line) 1, 3
- If digoxin fails, add or switch to sotalol or flecainide (second-line) 5, 1, 3
With hydrops fetalis:
- Sotalol shows superior efficacy compared to digoxin in hydropic fetuses 1
- Consider flecainide or amiodarone as alternatives 3, 6
The distinction matters because digoxin has poor placental transfer in the presence of hydrops, reducing its effectiveness 1. Atrial flutter and SVT respond similarly to these medications 1.
Monitor maternal cardiac function and electrolytes during antiarrhythmic therapy, as these drugs carry maternal risks 5, 7.
Atrioventricular Block
Complete heart block has limited response to prenatal treatment compared to tachyarrhythmias 3.
For fetal AV block, particularly with maternal anti-SSA/SSB antibodies:
- Consider dexamethasone for etiological treatment of antibody-mediated block 3, 6
- Beta-stimulants (salbutamol) may be used within study protocols 6
- Efficacy remains limited; focus on surveillance for heart failure 3
Critical Red Flags Requiring Immediate Intervention
- Sustained or worsening arrhythmia
- Development of hydrops fetalis
- Declining ventricular function
- Heart failure signs (cardiomegaly, valve regurgitation, reversed flow patterns) 8, 1
Delivery Planning
Timing of delivery depends on:
- Gestational age
- Response to medical therapy
- Presence of hydrops or heart failure
- Recurrent arrhythmia despite treatment 7
For refractory cases with hydrops or heart failure, consider delivery at a tertiary center with pediatric cardiology and neonatal intensive care immediately available 9, 7. Cesarean delivery at 35-37 weeks may be necessary for medically refractory cases 9, 7.
Postnatal Management
All neonates with prenatal arrhythmia require:
- Immediate postnatal ECG
- Pediatric cardiology evaluation
- Continued monitoring, as some arrhythmias recur or present postnatally 4, 7
For neonates with persistent tachyarrhythmia at delivery, intravenous antiarrhythmics (amiodarone, adenosine) or electrical cardioversion may be required 9.
Common Pitfalls
- Avoid atenolol for any fetal arrhythmia (Class III recommendation) 5
- Do not assume all irregular fetal heart rates are benign—distinguish PACs from AV block using echocardiography 4
- Do not delay treatment in the presence of hydrops; mortality increases significantly 1, 7
- Remember that approximately 27% of women with prior ventricular arrhythmias will have recurrence during pregnancy, requiring preconception counseling 8